Abselion has received the Best Antibody Discovery Platform 2026 – UK award in the GHP Biotechnology & Lifesciences Awards 2026, recognising the work behind the Amperia™ platform.
Amperia™ supports faster, simpler biologics quantification across research and biopharmaceutical workflows, helping teams generate actionable data from early discovery through to process development.
This recognition reflects the continued efforts of the Abselion team in developing accessible protein quantification solutions for biologics research and development.
Read more on the GHP winner profile: here